建聯集團(00385.HK)及建業建榮(01556.HK)擬收購元朗物業公司權益
建聯集團(00385.HK)及建業建榮(01556.HK)聯合公布訂立諒解備忘錄,建業建榮及建聯非全資附屬計劃以1.9億元收購目標公司先滿發展全部已發行股本之50%。
先滿發展為該物業之唯一合法及實益擁有人。物業於土地註冊處登記之新界元朗丈量約份128號地段163號A及B分段、地段164號、地段165號B分段1小分段、地段165號B分段餘下部分、地段165號D分段、地段165號、166號及167號餘下部分、地段168號、169號、170號及171號之一塊或一幅土地,連同其上之宅院、豎設物及樓宇。
公司指未就可能收購事項訂立正式協議,可能收購事項可能會亦可能不會進行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.